SEC Form 4 · accession 0001104659-17-074431
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen L Sabba
Director
Period of report
Dec 20, 2017
Accepted (ET)
Dec 21, 2017 · 6:31 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 20, 2017 | S | 925 | $137.25 | D | 26,985 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These securities, as represented in Column 5 and as previously reported in the Form 4 filed for this Reporting Person on May 30, 2017, include a grant of 666 restricted shares approved by the Board of Directors of the Company at the 2017 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.